KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Esperion Therapeutics (ESPR) Accumulated Depreciation & Amortization (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 5.06% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 5.06%, and an annual FY2025 reading of $2.2 million, up 5.06% over the prior year.
  • Accumulated Depreciation & Amortization was $2.2 million for Q4 2025 at Esperion Therapeutics, up from $2.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.6 million in Q4 2022 and bottomed at $2.0 million in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.2 million, with a median of $2.1 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 30.55% in 2021, then decreased 21.13% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $2.1 million in 2021, then rose by 24.38% to $2.6 million in 2022, then fell by 21.13% to $2.0 million in 2023, then rose by 3.08% to $2.1 million in 2024, then rose by 5.06% to $2.2 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ESPR at $2.2 million in Q4 2025, $2.1 million in Q4 2024, and $2.0 million in Q4 2023.